JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB277624

Anti-SARS-CoV-2 Spike Glycoprotein RBD antibody [2G1]

Be the first to review this product! Submit a review

|

(4 Publications)

Mouse Monoclonal SPIKE antibody. Suitable for ICC/IF, WB and reacts with Transfected cell line - SARS-CoV-2, Recombinant full length protein - SARS-CoV-2, Transfected cell lysate - SARS-CoV-2 samples. Cited in 4 publications. Immunogen corresponding to Recombinant Fragment Protein within SARS-CoV-2 S.

View Alternative Names

2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein

2 Images
Immunocytochemistry/ Immunofluorescence - Anti-SARS-CoV-2 Spike Glycoprotein RBD antibody [2G1] (AB277624)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-SARS-CoV-2 Spike Glycoprotein RBD antibody [2G1] (AB277624)

HEK-293 cells transfected with the DNA encoding the S-protein segment stained for spike glycoprotein using ab277624 (green) at 1/1000 dilution in Immunocytochemistry. The nuclei of transfected and untransfected cells are shown in blue with DAPI DNA stain.

Western blot - Anti-SARS-CoV-2 Spike Glycoprotein RBD antibody [2G1] (AB277624)
  • WB

Supplier Data

Western blot - Anti-SARS-CoV-2 Spike Glycoprotein RBD antibody [2G1] (AB277624)

Western blot analysis of cells transfected with DNA encoding the S-protein ACE2 binding site in PROT-SARS-CoV2-bd which was inserted into pCI-Neo-Mod or pCI-Neo-GFP eukaryotic expression vectors, which express either the insert only or the insert fused with GFP using ab277624 (green) at 1/3000 dilution. The blot was also stained with rabbit polyclonal control antibody to HSP60 (red) at 1/5000 dilution.

Lanes 1 and 5:

Western blot - Anti-SARS-CoV-2 Spike Glycoprotein RBD antibody [2G1] (ab277624)

Lanes 2, 3, 4, 6 and 7:

Western blot - Anti-SARS-CoV-2 Spike Glycoprotein RBD antibody [2G1] (ab277624) at 1/3000 dilution

Lanes 1 and 5:

Molecular weight ladder

Lane 2:

crude homogenate of untransfected control HEK-293 cells

Lane 3:

homogenate of HEK-293 cells expressing SARS-CoV2-bd

Lane 4:

homogenate of HEK-293 cells expressing GFP-SARS-CoV2-bd fusion

Lane 6:

full length recombinant SARS-CoV2 S-protein expressed in HEK293 at 1 µg

Lane 7:

full length recombinant SARS-CoV2 S-protein expressed in HEK293 at 0.1 µg

Observed band size: 60 kDa

false

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

2G1

Isotype

IgG1

Carrier free

No

Reacts with

SARS-CoV-2

Applications

ICC/IF, WB

applications

Immunogen

Recombinant Fragment Protein within SARS-CoV-2 S. The exact immunogen used to generate this antibody is proprietary information.

P0DTC2

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Recombinant full length protein - SARS-CoV-2": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/3000", "WB-species-notes": "<p></p>" }, "SARS-CoV": { "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "SARS-CoV-2": { "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Transfected cell line - SARS-CoV-2": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/1000", "ICCIF-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Transfected cell lysate - SARS-CoV-2": { "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/3000", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Purification notes
Purified from Tissue Culture supernatant.
Storage buffer
Preservative: 0.03% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike Glycoprotein Receptor Binding Domain (RBD) commonly referred to as 'anti-RBD' or 'COVID-19 RBD' plays a critical role in the viral entry mechanism of the SARS-CoV-2 virus. The RBD is part of the larger Spike (S) glycoprotein which has a molecular mass of about 180 kDa. This RBD is located on the surface of the virus and is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. Expression of the RBD occurs in the Spike protein which is synthesized during the viral replication cycle in infected host cells.
Biological function summary

The SARS-CoV-2 Spike Glycoprotein RBD initiates attachment to host cells by specifically binding to the ACE2 receptor facilitating viral entry. The RBD is part of a larger trimeric complex where each monomer consists of an S1 and S2 domain. The S1 domain which includes the RBD is important for receptor binding while the S2 domain aids in membrane fusion. By mediating these initial interactions with host cells the RBD dictates the entry and infectivity of the virus.

Pathways

The interaction of the SARS-CoV-2 RBD with ACE2 is an important event in the entry pathways of the virus. This interaction triggers a cascade of events leading to endocytosis and viral replication. The virus utilizes the cellular machinery by hijacking the ACE2-mediated entry pathway which involves proteolytic processing by transmembrane protease serine 2 (TMPRSS2). The RBD's role connects closely with these proteins playing a vital part in both viral fusion and endocytosis pathways.

The RBD of the SARS-CoV-2 Spike Glycoprotein is directly connected to COVID-19 the disease caused by the SARS-CoV-2 virus. This domain is a target for neutralizing antibodies such as 'anti-RBD' which can block the interaction with ACE2 potentially preventing infection. Additionally the RBD is implicated in COVID-19-related syndromes and conditions including severe acute respiratory distress syndrome. The Spike glycoprotein's significant interaction with ACE2 plays a role in the pathogenesis of these conditions by facilitating viral entry and propagation.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed : 32142651, PubMed : 32155444, PubMed : 33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed : 34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane (PubMed : 32075877, PubMed : 32221306, PubMed : 34903715, PubMed : 36779763). Alternatively, may use NRP1/NRP2 (PubMed : 33082294, PubMed : 33082293) and integrin as entry receptors (PubMed : 35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed : 33082293). Uses also ASGR1 as an alternative receptor in an ACE2-independent manner (PubMed : 34837059). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed : 32817270).. Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed : 32142651) or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
See full target information S

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

CNS neuroscience & therapeutics 30:e14822 PubMed38923860

2024

Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids.

Applications

Unspecified application

Species

Unspecified reactive species

Huimin Hu,Chen Wang,Rui Tao,Bohan Liu,Dazhao Peng,Yankun Chen,Wei Zhang

Clinica chimica acta; international journal of clinical chemistry 542:117279 PubMed36871661

2023

Designing and developing a sensitive and specific SARS-CoV-2 RBD IgG detection kit for identifying positive human samples.

Applications

Unspecified application

Species

Unspecified reactive species

Ehsan Raoufi,Fatemeh Hosseini,Bahman Onagh,Mohammad Salehi-Shadkami,Marjan Mehrali,Monireh Mohsenzadegan,Jim Q Ho,Banafsheh Bigdelou,Mohammad Reza Sepand,Thomas J Webster,Steven Zanganeh,Mohammad M Farajollahi

Frontiers in immunology 13:827146 PubMed35320941

2022

SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation.

Applications

Unspecified application

Species

Unspecified reactive species

Luca Perico,Marina Morigi,Miriam Galbusera,Anna Pezzotta,Sara Gastoldi,Barbara Imberti,Annalisa Perna,Piero Ruggenenti,Roberta Donadelli,Ariela Benigni,Giuseppe Remuzzi

Frontiers in immunology 12:803647 PubMed35095889

2022

Optimization of SARS-CoV-2 Spike Protein Expression in the Silkworm and Induction of Efficient Protective Immunity by Inoculation With Alum Adjuvants.

Applications

Unspecified application

Species

Unspecified reactive species

Akitsu Masuda,Jae Man Lee,Takeshi Miyata,Hiroaki Mon,Keita Sato,Kosuke Oyama,Yasuteru Sakurai,Jiro Yasuda,Daisuke Takahashi,Tadashi Ueda,Yuri Kato,Motohiro Nishida,Noriko Karasaki,Kohei Kakino,Takeru Ebihara,Takumi Nagasato,Masato Hino,Ayaka Nakashima,Kengo Suzuki,Yoshino Tonooka,Miyu Tanaka,Takato Moriyama,Hirokazu Nakatake,Ryosuke Fujita,Takahiro Kusakabe
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com